Tylenol in Pregnancy: No Autism, ADHD Link

In a significant development for expectant mothers and healthcare providers alike, new research has found no credible evidence linking Tylenol use during pregnancy to autism or attention-deficit/hyperactivity disorder (ADHD) in children. The comprehensive study, conducted by researchers at the University of Liverpool and published in the prestigious British Medical Journal (BMJ), should offer much-needed reassurance to millions of women who have used this common pain reliever during pregnancy.

Major Study Finds No Credible Link

Despite high-profile claims and a potential warning-label change by the U.S. Food and Drug Administration, a robust new analysis has found no clear connection between acetaminophen (the active ingredient in Tylenol) and neurodevelopmental conditions in offspring. The University of Liverpool researchers conducted an “umbrella review” – a high-level evidence summary that evaluates existing systematic reviews – to determine the scientific validity of claims linking maternal acetaminophen use to autism and ADHD.

“Through this work, we have shown that based on current evidence, there is no clear link between women taking paracetamol during pregnancy and a diagnosis of autism or ADHD in their children,” said lead researcher Professor Shakila Thangaratinam from the University of Liverpool. The study analyzed nine systematic reviews covering 40 observational studies on the topic, with four papers including meta-analyses.

Understanding the Research Methodology

An umbrella review is considered one of the highest forms of evidence in medical research, as it synthesizes multiple systematic reviews to provide a comprehensive overview of a topic. The Liverpool research team used rigorous strategies to assess each paper for bias, rating their confidence in the findings as high, moderate, low, or critically low.

Their analysis revealed that:

Seven out of nine reviews were rated as having critically low confidence
Two additional reviews were rated as having low confidence
Only one review included studies that properly adjusted for confounding genetic and environmental factors

Most significantly, when studies did account for critical parental health and lifestyle factors – including genetic predispositions, environmental exposures, and family mental health history – any apparent link between acetaminophen and neurodevelopmental disorders either vanished or became far less convincing.

Countering Previous Flawed Studies

The Liverpool study was conducted “in direct response to recent announcements” regarding acetaminophen safety, highlighting the varying quality among existing research. Many previous studies that suggested potential links failed to control for important variables that could influence neurodevelopmental outcomes.

“Current evidence does not demonstrate a clear link between paracetamol use in pregnancy and autism but our work also demonstrates how poor the data is around medications in pregnancy,” noted Professor Louise Kenny, Pro-Vice-Chancellor and Head of the Faculty of Health and Life Sciences at the University of Liverpool. This observation points to a broader issue affecting maternal health research.

The Broader Problem of Women’s Health Research

This umbrella review not only challenges previous claims but also reveals a concerning gap in medical research. The study authors emphasize the “wider problem of historic and continuing under investment in women’s health research,” particularly regarding medication safety during pregnancy.

Paracetamol (known as acetaminophen in the U.S.) remains one of the few over-the-counter medications recommended for pregnant women to treat pain and fever. As Professor Kenny noted, this lack of robust research affects healthcare providers’ ability to give evidence-based advice to pregnant women about other medications that might be necessary during pregnancy.

Public Health Implications and Controversy

The timing of this research is particularly significant given recent developments. In September 2025, the FDA initiated a process for a label change for acetaminophen products to reflect evidence suggesting that prenatal exposure may be associated with an increased risk of autism and ADHD. However, regulatory officials have emphasized that no causal relationship has been established.

Tylenol and Pregnancy

This scientific debate has taken on political dimensions, with public figures like former President Trump making claims about Tylenol and autism without scientific backing. Medical organizations have been quick to respond, with the American College of Obstetricians and Gynecologists (ACOG) maintaining that acetaminophen “remains the analgesic and antipyretic of choice during pregnancy.”

Both the American Academy of Pediatrics and ACOG continue to identify acetaminophen as one of the few pain relievers that can be used safely during pregnancy when taken as directed. According to a 2014 study, approximately 65 percent of pregnant women use acetaminophen, making it one of the most common medications taken during pregnancy.

Expert Guidance for Pregnant Women

Despite the controversy, medical experts continue to advise that pregnant women should not panic about previous acetaminophen use. As Dr. Zeyan Liew from Yale School of Public Health noted, “We do not know yet for sure whether acetaminophen causes autism. Multiple observational studies conducted across different populations have shown associations between frequent and prolonged acetaminophen use and increased risk of adverse neurodevelopmental outcomes, but these studies cannot establish causation.” The CDC also continues to provide guidance on safe medication use during pregnancy.

ACOG’s official position reinforces this perspective, stating that “suggestions that acetaminophen use in pregnancy causes autism are not only highly concerning to clinicians but also irresponsible when considering the harmful and confusing message they send to pregnant patients, including those who may need to rely on this beneficial medicine.” This guidance is consistent with ACOG’s broader recommendations on reproductive health services.

Limitations and Future Research

Like all research, this umbrella review has limitations. The researchers acknowledge the difficulty in comparing studies that varied in length, timing, and dosage of acetaminophen use. However, even with these variations, they conclude that “the lack of robust evidence linking paracetamol use in pregnancy and autism and ADHD in offspring” remains clear.

The study highlights the need for more rigorous, well-funded research into medication safety during pregnancy. This lack of data affects not just acetaminophen but the broader landscape of prenatal care and medication management. As researchers emphasize, properly conducted studies that account for confounding factors are essential for providing accurate medical guidance to pregnant women.

Conclusion

This comprehensive umbrella review provides strong reassurance to pregnant women and healthcare providers: current evidence does not support a link between acetaminophen use during pregnancy and autism or ADHD in children. While previous studies raised concerns, the Liverpool researchers have demonstrated that these links were largely artifacts of poor study design rather than genuine causal relationships.

The study should help healthcare professionals give evidence-based advice to women and reassure mothers about the use of acetaminophen during pregnancy when medically indicated. As the FDA continues to evaluate medication safety during pregnancy, this research provides an important foundation for evidence-based decision-making.

For expectant mothers who have used or are considering using acetaminophen for pain relief or fever management, this research offers reassurance that, when used as directed, this common medication does not appear to increase the risk of neurodevelopmental conditions in their children. However, as always, consultation with healthcare providers about any medication use during pregnancy remains essential.